Share
Byondis
Algemeen bedrijfsprofiel
Driven to improve patients’ lives, Byondis is an independent, privately held, Dutch clinical stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing next generation antibody-drug conjugates (ADCs), monoclonal antibodies (mAbs) and new chemical entities (NCEs) that can stand alone or be incorporated in its ADCs.
Byondis’ broad development portfolio comprises preclinical as well as early- and late-stage clinical development programs. The company has a dedicated team of about 400 employees, including highly educated scientists and skilled technicians working in state-of-the-art R&D and Good Manufacturing Practice (GMP) production and conjugation facilities on its campus in Nijmegen. Byondis regularly collaborates with leading global biotechnology and pharmaceutical companies, as well as many academic research institutions. For more information, visit www.byondis.com.
Byondis’ broad development portfolio comprises preclinical as well as early- and late-stage clinical development programs. The company has a dedicated team of about 400 employees, including highly educated scientists and skilled technicians working in state-of-the-art R&D and Good Manufacturing Practice (GMP) production and conjugation facilities on its campus in Nijmegen. Byondis regularly collaborates with leading global biotechnology and pharmaceutical companies, as well as many academic research institutions. For more information, visit www.byondis.com.
Bedrijfsactiviteiten
We create precision medicines, based on patient-focused drug development, which bring innovative therapeutic solutions to patients with key unmet medical needs.
Our development programs are targeting specific intractable cancers and autoimmune diseases with the aim of creating innovative, safe and effective precision medicines, based on new biological entities: antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). We develop new biological entities (NBEs) and new chemical entities (NCEs) using proprietary molecular concepts, such as ByonZine®, our duorcarmazine linker-drug (LD) technology and ByonShieLD®, our site-specific conjugation technology, to generate next generation ADC’s.
Our development programs are targeting specific intractable cancers and autoimmune diseases with the aim of creating innovative, safe and effective precision medicines, based on new biological entities: antibody-drug conjugates (ADCs) and monoclonal antibodies (mAbs). We develop new biological entities (NBEs) and new chemical entities (NCEs) using proprietary molecular concepts, such as ByonZine®, our duorcarmazine linker-drug (LD) technology and ByonShieLD®, our site-specific conjugation technology, to generate next generation ADC’s.
We zoeken
Frequently we are looking for all kinds of employees. From technician for our manufacturing until researchers for our research and development programs and much more. Look at our careersite for our vacancies: careers.byondis.com
We bieden
Besides a competitive salary, we offer you a dynamic working environment at our state-of-the-art campus in Nijmegen. Our values of integrity, authenticity, entrepreneurship, quality and trust are very highly regarded. We aim to create an engaging and collaborative environment for all of our employees. We also offer an excellent pension scheme, 30 days of annual leave based on a full-time position, and we host several exciting company events throughout the year.
Company info
Adres
Microweg 22
6545 CM Nijmegen
6545 CM Nijmegen
Naam contactpersoon
Marjolijn van der Schoot
E-mail
recruitment@byondis.com
Telefoonnummer
+31(0)246795100
Aantal vestigingen
1
Website
www.byondis.com
Aantal medewerkers
400
Actief in de sectoren
Bio/Life Sciences, Pharma
Type organisatie
MKB (midden en kleinbedrijf)